Nature of the Journal
The Journal of Cancer and Translational Oncology (JCTO) is an international, peer-reviewed, open-access scholarly journal dedicated to advancing research in oncology, cancer biology, and translational medicine.
The journal is research-driven in nature and focuses on publishing high-quality scientific, clinical, and experimental studies that contribute to a deeper understanding of cancer mechanisms, diagnosis, treatment strategies, and patient care outcomes.
It serves as a global platform for researchers, clinicians, and healthcare professionals to share innovative discoveries and advancements that bridge the gap between laboratory research and clinical practice. The journal strongly emphasizes translational research that transforms scientific findings into effective medical applications.
The journal encourages interdisciplinary collaboration across oncology, molecular biology, genetics, immunology, pharmacology, biotechnology, biomedical engineering, and clinical sciences. It also supports emerging technologies such as personalized medicine, immunotherapy, and advanced diagnostic tools.
All manuscripts submitted to the journal undergo a rigorous peer-review process to ensure scientific validity, originality, and clinical relevance. Only research that meets high ethical and methodological standards is accepted for publication.
The journal operates under a full open-access publishing model, ensuring that all published articles are freely available worldwide without subscription barriers. This promotes rapid dissemination of knowledge and supports global research collaboration.
The Journal of Cancer and Translational Oncology publishes a variety of article types, including research articles, review papers, clinical studies, case reports, and other scholarly contributions that support scientific and medical advancement in oncology.
Through its commitment to ethical publishing, scientific excellence, and translational innovation, the journal aims to contribute significantly to the global progress of cancer research and improved patient outcomes.
